The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Self-citationMPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Self-citationJAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020150 · Cited by 630
Krutzik, P. O., & Nolan, G. P. (2003) · Cytometry Part A · doi:10.1002/cyto.a.10072 · Cited by 562
Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2005-12-4824 · Cited by 483
Self-citationLacout, C., Pisani, D. F., Tulliez, M., Gachelin, F. M., Vainchenker, W., & Villeval, J.-L. (2006) · Blood · doi:10.1182/blood-2006-02-002030 · Cited by 435
Bone-Marrow Responses in Polycythemia Vera
(1974) · New England Journal of Medicine · doi:10.1056/nejm197406132902419 · Cited by 420
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Self-citationLenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253
Self-citationLevine, R. L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland, D. G., & Busque, L. (2006) · Blood · doi:10.1182/blood-2005-09-3900 · Cited by 241
Self-citationMolecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Zaleskas, V. M., Krause, D. S., Lazarides, K., Patel, N., Hu, Y., Li, S., & Van Etten, R. A. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000018 · Cited by 220
Cited by
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
“Several companies have generated putatively selective Jak2 inhibitors, which are being tested in these disorders including S*BIO (SB1518), Exelixis (XL019), Incyte (INCB018424), TargeGen (TG101348), and Cephalon (lestaurtinib) (141, 142).”
BackgroundTargeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Sansone, P., & Bromberg, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8907 · Cited by 515
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 400
Self-citationMullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.015 · Cited by 395
Self-citationNew mutations and pathogenesis of myeloproliferative neoplasms
Vainchenker, W., Delhommeau, F., Constantinescu, S. N., & Bernard, O. A. (2011) · Blood · doi:10.1182/blood-2011-02-292102 · Cited by 395
Metadata
- Authors
- Wernig, G., Kharas, M. G., Okabe, R., Moore, S. A., Leeman, D. S., Cullen, D. E., Gozo, M., McDowell, E. P., Levine, R. L., Doukas, J., Mak, C. C., Noronha, G., Martin, M., Ko, Y. D., Lee, B. H., Soll, R. M., Tefferi, A., Hood, J. D., & Gilliland, D. G.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2008-04
- Volume
- 13
- Issue
- 4
- Pages
- 311-320
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1995981641
- Cited by
- 390
- References
- 22
- FWCI
- 18.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.